Press Releases for OSCI

Press Releases
Oscient Pharmaceuticals Files Voluntary Petition for Relief Under Chapter 11 of the United States Bankruptcy Code
Cornerstone Therapeutics Signs Definitive Asset Purchase Agreement to Acquire Commercial Rights to the Antibiotic Factive(R)
Oscient Pharmaceuticals Discontinues Sales Force Promotion for ANTARA and FACTIVE
Oscient Pharmaceuticals Receives NASDAQ Letter Regarding Delay in Filing Form 10-Q
Oscient Pharmaceuticals Files Form 12b-25 Notification of Late Filing for Form 10-Q for Quarterly Period Ended March 31, 2009
Lazard Ltd Reports First-Quarter 2009 Results
Oscient Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Financial Results
Webcast Alert: Oscient Pharmaceuticals Announces Date for Release of Fourth Quarter Financial Results
NASDAQ Extends Temporary Suspension of Bid Price and Market Value of Publicly Held Shares Requirements; Oscient Compliance Period Extended to October 6, 2009
Oscient Pharmaceuticals Restructures Commercial Organization
Oscient Pharmaceuticals Extends Maturity of its Privately Placed 5% Convertible Promissory Notes
Oscient Pharmaceuticals and Ethypharm SA File Lawsuit Against Lupin for Infringement of ANTARA® Patent
NASDAQ Extends Temporary Suspension of Bid Price and Market Value of Publicly Held Shares Requirements; Oscient Compliance Period Extended to July 6, 2009
Oscient Pharmaceuticals Announces Management Change
Oscient Pharmaceuticals Receives Paragraph IV Certification Notice for ANTARA
Oscient Pharmaceuticals Announces Successful Completion of Convertible Debt Exchange Offer
Oscient Pharmaceuticals Announces Determination of the Consideration Issuable in its Exchange Offer
Oscient Pharmaceuticals to Participate in the Lazard Capital Markets 5th Annual Healthcare Conference
Oscient Pharmaceuticals Amends Exchange Offer
Oscient Pharmaceuticals to Participate in the Rodman & Renshaw 10th Annual Healthcare Conference
Oscient Pharmaceuticals Reports Third Quarter 2008 Financial Results
Webcast Alert: Oscient Pharmaceuticals Announces Date for Release of Third Quarter Financial Results
NASDAQ Implements Temporary Suspension of Bid Price and Market Value of Publicly Held Shares Requirements; Oscient Compliance Period Extended to April 7, 2009
Oscient Pharmaceuticals Commences Exchange Offer
Oscient Pharmaceuticals Receives NASDAQ Notice
Oscient Pharmaceuticals Seeks to Improve Capital Structure through Proposed Exchange Offer with Holders of its 3.50% Convertible Senior Notes due 2011
Oscient Pharmaceuticals to Participate in the Fourth Annual Noble Financial Equity Conference
Oscient Pharmaceuticals to Participate in the BMO Capital Markets Focus on Healthcare Conference
Oscient Pharmaceuticals Reports Second Quarter 2008 Financial Results
Oscient Pharmaceuticals Promotes Mark A. Glickman to Senior Vice President, Sales and Marketing
Webcast Alert: Oscient Pharmaceuticals Announces Date for Release of Second Quarter Financial Results
Regulatory Filing for FACTIVE Tablets Submitted in Europe - Jun 2 2008 1:04AM
Oscient Pharmaceuticals Reports First Quarter 2008 Financial Results - Jun 2 2008 1:04AM
Webcast Alert: Oscient Pharmaceuticals Announces Date for Release of First Quarter Financial Results - Jun 2 2008 1:04AM
Oscient Pharmaceuticals Provides Preliminary Revenue Results for First Quarter 2008